Abstract Posters – Monday 23rd April at WFNMB2018
Theranostics Australia’s Dr. Danielle Meyrick (Chief Scientific Officer) displayed TWO abstract submissions as posters yesterday in the Exhibition Hall at the #WFNMB2018 Conference.
(3) 68Ga-PSMA-PET/CT is Superior to Contrast CT in Rising PSA Post Definitive Treatment for Prostate Cancer (P140).
(4) Initial Experience with 1 year Follow Up in 22 Patients Treated with Lu-177 I&T PSMA for Advanced Prostate Cancer – Safety, Efficacy and Quality of Life (P199).
All 4 of TA’s posters from the WFNMB Conference will be made available this week.